NeoGenomics announces executive leadership and board succession plan
NEO•NeoGenomics appointed Warren Stone as CEO and board member, Tony Zook as executive chairman, and Michael Kelly as lead independent director, effective Jan. 4, 2027. The company expects preliminary third-quarter revenue of $209 million, about 28% NGS revenue growth, and a higher midpoint for full-year revenue guidance.
1. Leadership succession
NeoGenomics said Warren Stone will become CEO and a board member, Tony Zook will become executive chairman, and Michael Kelly will become lead independent director, all effective Jan. 4, 2027. Current chair Lynn Tetrault will remain an independent director until the 2027 annual meeting and will not stand for reelection.
2. Revenue outlook
The company expects preliminary third-quarter revenue of $209 million and NGS revenue growth of about 28%. It also expects to increase the midpoint of its full-year total revenue guidance.
